Symbiotec Pharmalab Ltd. (Mainboard) IPO
Symbiotec Pharmalab is a pharmaceutical and biotechnology company with over 30 years of experience. It mainly manufactures Corticosteroid and Steroidal Hormone APIs, which are important ingredients used to make medicines.
IPO GMP
+₹185
+19% expected gain
Price Band
₹938 - ₹988
Lot Size
15 shares
Min Investment
₹14,820
Listing Date
September 1, 2026
About Symbiotec Pharmalab Ltd. (Mainboard)
Company overview, business, and key facts.
Symbiotec Pharmalab is a pharmaceutical and biotechnology company with over 30 years of experience. It mainly manufactures Corticosteroid and Steroidal Hormone APIs, which are important ingredients used to make medicines.
The company has grown from a small laboratory-scale steroid manufacturer into a fully integrated global company. In FY2025, Symbiotec had a strong share of the global market for these APIs and was the only Indian and global company present across the top 10 categories in this market.
In FY2025, they were a global leader by volume in the production of Corticosteroid and Steroidal-Hormone Active Pharmaceutical Ingredients (APIs).
Headquarters
Indore, Madhya Pradesh
Promoters
Anil Satwani, Kashish Satwani, Sushil Satwani, Satwani Holdings LLP
Website
http://www.symbiotec.com/
IPO Details
Subscription Status
How many times each investor category has bid for the issue.
Strengths & Risks
Strengths
- Review: May Apply
Risks
- Regulatory and quality compliance risk: The manufacturing facilities of the company are subject to inspection by regulatory agencies and its customers. Failure at either manufacturing or quality control will have regulatory, reputational, and business impacts on the company.
- Export market dependence: The firm earns a considerable percentage of income through foreign clients who have accounted for 66.67%, 55.19%, 59.97%, and 52.76% of the firm’s revenue from operations during the three months to June 30, 2025 and Fiscals 2025, 2024, and 2023, respectively. Failure to mitigate risks inherent to overseas sales may impact overseas income and performance.
- Imported Raw Material Dependence: The business is dependent on imported raw material, which comes from countries such as China and the United States. Any adverse events in those countries and any changes in the laws that govern imports will hinder the supply of raw materials and negatively impact the business performance.
Financials
Restated summary financials for the most recent periods.
Figures are indicative and restated for presentation.
Symbiotec Pharmalab Ltd. (Mainboard) IPO Key Numbers
Calculated by IPOLyst from the published offer-document data. These are figures, not buy or sell calls.
Market cap at upper band
₹6,244.4 Cr
Post-IPO shares × upper price band
P/E on 2026 profit
56.8x
Peer median 91.4x (discount of 37.9%)
Price to sales
7.16x
Revenue growth, 2026
+15.4%
9.8% a year over the period
Profit growth, 2026
+13.5%
4.8% a year over the period
Profit margin (PAT)
12.6%
EBITDA margin 26.59%
ROE / ROCE
11.19% / 11.56%
As published in the offer document
Issue mix
8.5% fresh / 91.5% sale
Fresh issue goes to the company, offer for sale to selling shareholders
GMP-implied gain per lot
₹2,775
15 shares on ₹14,820. GMP is unofficial.
What stands out
- Priced at a 37.9% discount to the peer median P/E of 91.4.
Watch-outs
- 91.5% of the issue is an offer for sale, so most money goes to selling shareholders, not the company.
- 100% of the disclosed use of proceeds is debt repayment.
- 1 use-of-proceeds item(s) have no disclosed amount.
Scenarios apply today's grey market premium figures to the upper price band. They are illustrations, not predictions. GMP is unofficial and can be wrong.
IPO Analysis SummaryAI-generated
A plain-language review of Symbiotec Pharmalab Ltd. (Mainboard)'s financials, valuation and demand, based only on the verified figures above. For information only. It does not recommend whether to apply.
Symbiotec Pharmalab Ltd. (Mainboard) IPO Review
Analysis based on live GMP, subscription, and issue details.
As of today, Symbiotec Pharmalab Ltd. (Mainboard) IPO is trading at a grey market premium (GMP) of +₹185 (+19% estimated listing gain), indicating positive market sentiment.
The IPO has been subscribed 71.26x overall — QIB: 172.03x, NII: 73.63x, Retail: 12.96x.
Symbiotec Pharmalab Ltd. (Mainboard) IPO subscription has closed. The shares are expected to list on September 1, 2026.
The minimum investment required is ₹14,820 for 15 shares (1 lot). Retail investors can apply at cut-off price for the best chance of allotment.
Key strengths include: Review: May Apply. Investors should note the following risks: Regulatory and quality compliance risk: The manufacturing facilities of the company are subject to inspection by regulatory agencies and its customers. Failure at either manufacturing or quality control will have regulatory, reputational, and business impacts on the company.; Export market dependence: The firm earns a considerable percentage of income through foreign clients who have accounted for 66.67%, 55.19%, 59.97%, and 52.76% of the firm’s revenue from operations during the three months to June 30, 2025 and Fiscals 2025, 2024, and 2023, respectively. Failure to mitigate risks inherent to overseas sales may impact overseas income and performance..
Disclaimer: IPO GMP is indicative and sourced from the grey market. This is not investment advice. Please consult a SEBI-registered advisor before investing.
Symbiotec Pharmalab Ltd. (Mainboard) IPO — Frequently Asked Questions
What is Symbiotec Pharmalab Ltd. (Mainboard) IPO GMP today?
Symbiotec Pharmalab Ltd. (Mainboard) IPO GMP (grey market premium) today is +₹185, suggesting an estimated listing gain of +19%. GMP is indicative and subject to change.
What is the price band of Symbiotec Pharmalab Ltd. (Mainboard) IPO?
The price band for Symbiotec Pharmalab Ltd. (Mainboard) IPO is ₹938 - ₹988 with a lot size of 15 shares. The minimum investment required is ₹14,820.
When is Symbiotec Pharmalab Ltd. (Mainboard) IPO allotment date?
Symbiotec Pharmalab Ltd. (Mainboard) IPO allotment is expected to be finalised on August 28, 2026. You can check your allotment status on the registrar's website (MUFG Intime India Pvt. Ltd.) using your PAN number.
When will Symbiotec Pharmalab Ltd. (Mainboard) IPO list on NSE/BSE?
Symbiotec Pharmalab Ltd. (Mainboard) IPO is expected to list on BSE, NSE on September 1, 2026.
How to check Symbiotec Pharmalab Ltd. (Mainboard) IPO allotment status?
To check Symbiotec Pharmalab Ltd. (Mainboard) IPO allotment status, visit the registrar's website (MUFG Intime India Pvt. Ltd.) and enter your PAN number, application number, or DP/Client ID. You can also check on the BSE IPO allotment page at https://www.bseindia.com/investors/appli_check.aspx.
Should I apply for Symbiotec Pharmalab Ltd. (Mainboard) IPO?
Symbiotec Pharmalab Ltd. (Mainboard) IPO is showing a strong GMP of +₹185 (+19%), indicating positive market sentiment for listing gains. However, GMP is informal and not a guarantee of returns. Evaluate the company's fundamentals, price band, and your own risk appetite before applying. IPOLyst is not a SEBI-registered investment advisor — please do your own research.
What is the lot size of Symbiotec Pharmalab Ltd. (Mainboard) IPO?
The lot size for Symbiotec Pharmalab Ltd. (Mainboard) IPO is 15 shares per lot. The minimum investment for retail investors is ₹14,820. Retail investors can apply for a maximum of 13 lots or up to ₹2 lakh, whichever is lower.